Press "Enter" to skip to content

AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer – PMLiVE

admin 0

AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer  PMLiVE

AstraZeneca’s Imfinzi is the latest PD-1/PD-L1 inhibitor to show clinical activity in small cell lung cancer (SCLC), extending survival when used as a first-line …

“bladder cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *